for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Idorsia Ltd

IDIA.S

Latest Trade

26.44CHF

Change

0.62(+2.40%)

Volume

1,182,416

Today's Range

25.74

 - 

26.48

52 Week Range

18.69

 - 

33.88

As of on the SIX Swiss Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
25.82
Open
25.80
Volume
1,182,416
3M AVG Volume
14.11
Today's High
26.48
Today's Low
25.74
52 Week High
33.88
52 Week Low
18.69
Shares Out (MIL)
142.64
Market Cap (MIL)
3,771.53
Forward P/E
-7.80
Dividend (Yield %)
--

Latest Developments

More

Santhera Pharmaceuticals A Direct License Holder Of Vamorolone

Idorsia Selects Syneos Health As Commercialization Partner To Launch Daridorexant In US

Idorsia H1 Non-GAAP Operating Expenses At CHF 193 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Idorsia Ltd

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Industry

Biotechnology & Drugs

Contact Info

Hegenheimermattweg 91

4123

Switzerland

+41.58.8441010

https://www.idorsia.com

Executive Leadership

Jean-Pierre Garnier

Non-Executive Independent Chairman of the Board

Jean-Paul Clozel

Chief Executive Officer, Delegate of the Board, Member of the Executive Board

Andre C. Muller

Chief Financial Officer, Executive Vice President, Member of the Executive Board

Martine Clozel

Executive Vice President, Chief Scientific Officer, Member of the Executive Board

Simon Jose

Executive Vice President, Chief Commercial Officer, Member of the Executive Board

Key Stats

2.33 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, CHF)

2017

0.2K

2018

0.1K

2019

0.0K

2020(E)

0.1K
EPS (CHF)

2017

0.030

2018

-3.100

2019

-3.760

2020(E)

-3.390
Price To Earnings (TTM)
--
Price To Sales (TTM)
54.77
Price To Book (MRQ)
11.75
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
182.10
LT Debt To Equity (MRQ)
182.10
Return on Investment (TTM)
-41.49
Return on Equity (TTM)
-37.35

Latest News

Latest News

Johnson & Johnson's Cilag to sell up to 11.8 million Idorsia shares

Johnson & Johnson's <JNJ.N> Cilag Holding will offer up to approximately 11.8 million existing ordinary shares in Idorsia Ltd <IDIA.S> in an accelerated bookbuilding to commence on Wednesday, the transaction's bookrunner said.

BRIEF-Cilag Holding Announces Proposed Offering Of Up To About 11.8 Mln Shares In Idorsia

* PROPOSED OFFERING OF UP TO APPROXIMATELY 11.8 MILLION EXISTING ORDINARY SHARES IN IDORSIA LTD

BRIEF-Idorsia: Positive Results In Second Phase 3 Study Of Daridorexant

* ANNOUNCES POSITIVE RESULTS IN SECOND PHASE 3 STUDY OF DARIDOREXANT

Idorsia raises $340 mln in new share offering

Idorsia has raised 330 million Swiss francs ($340.31 million) from a share offering, the Swiss drugmaker said on Wednesday, as it bolsters its coffers for the planned launch of an insomnia drug and for research and development.

BRIEF-Idorsia Completes Offering Of New Shares

* IDORSIA SUCCESSFULLY COMPLETES THE OFFERING OF NEW SHARES THEREBY SECURING FUNDING FOR THE COMPANY’S GROWTH PLAN

BRIEF-Idorsia Launches Offering Of New Shares

* IDORSIA LAUNCHES AN OFFERING OF NEW SHARES TO FUND THE COMPANY’S GROWTH PLAN

BRIEF-Idorsia: Neurocrine Biosciences Exercises Option To License Idorsia's Novel Treatment For Rare Pediatric Epilepsy

* NEUROCRINE BIOSCIENCES EXERCISES OPTION TO LICENSE IDORSIA'S NOVEL TREATMENT FOR RARE PEDIATRIC EPILEPSY

BRIEF-Neurocrine Biosciences Exercises Option To License Idorsia's Treatment For Pediatric Epilepsy

* NEUROCRINE BIOSCIENCES INC - EXERCISES OPTION TO LICENSE IDORSIA'S NOVEL TREATMENT FOR RARE PEDIATRIC EPILEPSY

BRIEF-Idorsia Q1 US GAAP Operating Loss Of CHF 111 Mln

* US GAAP Q1 DILUTED EPS LOSS 0.91 CHF VERSUS 0.81 CHF LOSS YEAR AGO

Idorsia's insomnia drug works in late-stage clinical trial

Swiss drugmaker Idorsia Ltd's experimental insomnia drug daridorexant produced positive results in a late-stage clinical trial, the company said on Monday.

BRIEF-Idorsia Announces Positive Results In First Phase 3 Study Of Daridorexant

* IDORSIA ANNOUNCES POSITIVE RESULTS IN THE FIRST PHASE 3 STUDY OF DARIDOREXANT WITH IMPROVED OVERALL SLEEP AND DAYTIME PERFORMANCE OF PATIENTS WITH INSOMNIA Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Idorsia: Janssen Submits New Drug Application To FDA

* JANSSEN ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO THE U.S. FDA FOR PONESIMOD FOR TREATMENT OF ADULTS WITH RELAPSING MULTIPLE SCLEROSIS

Idorsia pairs with Neurocrine in potential $400 million epilepsy drug deal

Swiss biotech group Idorsia on Friday lifted the lid off a 2019 deal for its investigational epilepsy medicine, revealing the pact that is potentially worth more than $400 million is with U.S.-based Neurocrine Biosciences.

BRIEF-Idorsia And Neurocrine Biosciences Amend Option Agreement On Treatment For Pediatric Epilepsy

* NEUROCRINE BIOSCIENCES AND IDORSIA AMEND OPTION AGREEMENT TO LICENSE NOVEL TREATMENT FOR RARE PEDIATRIC EPILEPSY

BRIEF-Idorsia And Mochida Enter Into License Agreement

* IDORSIA AND MOCHIDA ENTER INTO A LICENSE AGREEMENT FOR THE SUPPLY, CO-DEVELOPMENT AND CO-MARKETING OF DARIDOREXANT IN JAPAN

Idorsia's Clozel says recruitment delay won't dent Fabry drug prospects

Fledgling Swiss biotech Idorsia has suffered delays in recruiting patients for a key trial of its experimental lucerastat drug but that will not damage its commercial prospects, founder Jean-Paul Clozel told Reuters on Tuesday.

BRIEF-Idorsia 9-Month US GAAP Operating Loss CHF 355 Million

* US GAAP REVENUE OF CHF 20 MILLION IN FIRST NINE MONTHS OF 2019 AS WELL AS 2018

BRIEF-Idorsia Says Janssen Reports Positive Top-Line Phase 3 Results For Ponesimod

* JANSSEN REPORTS POSITIVE TOP-LINE PHASE 3 RESULTS FOR PONESIMOD IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS

BRIEF-Idorsia H1 US GAAP Net Loss At CHF 232 Mln

* UNCHANGED GUIDANCE FOR 2019: US GAAP OPERATING EXPENSES OF AROUND CHF 570 MILLION

UPDATE 1-Idorsia confirms 2019 spending plan as clinical trials "on track"

Swiss biotech Idorsia said on Thursday that all four clinical trials of its late-stage drug hopefuls were "on track" as it confirmed expectations of spending 570 million Swiss francs ($564 million) in the current year on the projects.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up